Abstract 92P
Background
The management of breast cancer (BC) is rapidly developing with important new data being presented and published. This micro-learning CME series shared clinical cases highlighting the recent latest advances in early & metastatic BC. Learners were evaluated on their knowledge of the latest data, competence in the management of adverse events and confidence in their ability to identify appropriate treatment options for patients.
Methods
The outcomes of 6 short medical educational (CME) chapters (video with accompanying slides) were evaluated. The educational impact was assessed with a repeated pairs design, participants were questioned pre-education and post-education (knowledge/competence & confidence). The questions and the outcomes data were divided into 8 topics, 2 covering ER+ breast cancer; 1 on gBRCA mutated early BC; 3 on HER2+ (after 1L) and 2 on HER2-Low metastatic breast cancer. Data were collected from 29th August to 9th December 2022. Statistical significance was assessed using McNemar’s test (P < .05 level).
Results
A total of 3,202 HCPs participated in these activities, of whom 439 were oncologists and 409 were obstetrics/gynaecology physicians. Significant overall improvements were observed in the knowledge and competence of Oncologists and Ob/Gyns as shown below: Table: 92P
| Oncologists (% of correct responses) | % improvement & P-value | Ob/Gyns (% of correct responses) | % improvement & P-value | |
| Pre-education | 50% | 75%P<.001 | 25% | 69%P<.001 |
| Post-education | 71% | 41% | ||
| KEY OUTCOMES | ||||
| ER+ BC | Pre 37%; Post 66% | 78%↑ | Pre 16%; Post 34% | 113%↑ |
| gBRCA EBC | Pre 60%; Post 86% | 43%↑ | Pre 38%; Post 55% | 45%↑ |
| HER2+ AEs | Pre 78%; Post 96% | 23%↑ | Pre 41%; Post 68% | 66%↑ |
| Diagnosing HER2 Low BC | Pre 38%; Post 38% | 0% | Pre 14%; Post 14% | 0% |
Conclusions
This micro CME educational program demonstrated a statistically significant improvement in knowledge/competence and confidence for all HCPs who completed the assessments. Outcomes by chapter showed a positive impact for each activity except the HER2-Low disease case. With recent developments in the identification and treatment of HER2-Low BC, this data underlines the need for ongoing education to help HCPs understand this important BC population.
Legal entity responsible for the study
Web MD Global / Medscape Education.
Funding
Medscape Global Education using an independent educational grant from AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.